The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.
- Abstract:
- Vascular and angiogenic processes provide an important target for novel cancer therapeutics. Dynamic contrast-enhanced magnetic resonance imaging is being used increasingly to noninvasively monitor the action of these therapeutics in early-stage clinical trials. This publication reports the outcome of a workshop that considered the methodology and design of magnetic resonance studies, recommending how this new tool might best be used.
- Authors:
- MO Leach, KM Brindle, JL Evelhoch, JR Griffiths, MR Horsman, A Jackson, GC Jayson, IR Judson, MV Knopp, RJ Maxwell, D McIntyre, AR Padhani, P Price, R Rathbone, GJ Rustin, PS Tofts, GM Tozer, W Vennart, JC Waterton, SR Williams, P Workman, Pharmacodynamic/Pharmacokinetic Technologies Advisory Committee, Drug Development Office, Cancer Research UK
- Journal:
- Br J Cancer
- Citation info:
- 92(9):1599-1610
- Publication date:
- 9th May 2005
- Full text
- DOI